Yamo Pharmaceuticals Is Developing L1 79A Novel Therapy That Targets The Core Symptoms Of Autism And Has Been Well Tolerated By Clinical Trial Patients To Datethe Mechanism Of Action For L1 79 Addresses Both The Central Nervous System And Metabolic Symptoms Of Autism
No conferences found for this company.
| Company Name | Yamo Pharmaceuticals Llc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
Enter your address and we will specify the offer for your area.